Damora Therapeutics walks into its May 14 earnings release with short sellers having nearly doubled their positions in six weeks — a striking build in a small-cap biotech that has already shed 11% over the past month.
Short interest has climbed from roughly 1.2% of the free float in late March to close to 3% now, a gain of more than 128% in a month. The borrow market reflects that pressure: cost to borrow has been running around 16–20% APR through most of April and May, well above typical biotech levels. Availability has oscillated sharply — hitting fully tight (100% utilisation) on multiple days before easing back — which points to a lending pool that remains contested rather than comfortably supplied. The stock itself closed at $23.09 on Tuesday, down 5.2% on the day and 7.2% on the week, trading below the mid-March high of $32.30.
The analyst consensus tells a more constructive story. Five analysts rate DMRA a buy, with RBC Capital initiating at Outperform with a $40 target in late April — the most recent coverage addition — following Evercore ISI's Outperform initiation in March at $46. The mean target of $46.20 implies roughly double the current price, a substantial gap that reflects genuine bull conviction on the clinical pipeline rather than a crowded, consensus-driven setup. Bears have clearly taken a different view of near-term catalysts: the short build over the past six weeks happened largely while those analyst initiations were landing, suggesting the market is sharply divided on what tomorrow's update will show.
History adds an extra layer of volatility risk. The three most recent earnings events all produced double-digit one-day moves — ranging from a 15% drop to a 37% surge — and in each case the five-day move was large in the opposite direction. That pattern of sharp initial reactions followed by reversals says the stock is prone to violent repositioning around results, whichever way the first print lands.
The earnings report will test whether the clinical progress Damora's bullish initiating analysts are pricing in can quiet a short community that has been building conviction in the face of the recent rally.
See the live data behind this article on ORTEX.
Open DMRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
